# A Call for Updates to Hormone Therapy Guidelines for Gender-Diverse Adults Assigned Male at Birth

## TL;DR

This editorial highlights the need for updated hormone therapy guidelines for gender-diverse individuals assigned male at birth due to inconsistent treatment and lack of high-quality research.

## Contribution

The paper calls for more evidence-based research and personalized approaches to hormone therapy for AMAB individuals.

## Key findings

- Current hormone therapy regimens for AMAB individuals vary significantly.
- High-quality research and patient-reported outcome measures are lacking in this area.
- Guideline-based dosing recommendations show discrepancies that need addressing.

## Abstract

Gender-affirming hormone therapy for assigned male at birth (AMAB) individuals with gender incongruence typically consists of estradiol with or without an anti-androgen to achieve physical changes and psychological benefits. However, prescribed hormone regimens vary considerably, and high-quality research in this area is extremely limited. Additional evidence-based research evaluating patient-reported outcome measures (PROMs) is needed to fill current knowledge gaps and create a personalized therapeutic approach for AMAB individuals. This editorial provides a critical description of current treatment options, discusses their variability, reviews some discrepancies in guideline-based dosing recommendations, and recommends areas for further study.